Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 8/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043671 | 0.88 | ACACB (0.50) | ACACBMAOBMAOAKDM4EMEN1 | |
| SCHEMBL5043403 | 0.85 | ACACB (0.52) | ACACBMEN1MAPTRAB9AKMT2A | |
| SCHEMBL5043437 | 0.85 | ACACB (0.51) | ACACBAPPKDM4EMEN1MAPT | |
| SCHEMBL5043418 | 0.82 | ACACB (0.47) | ACACBMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL5043428 | 0.82 | ACACB (0.49) | ACACBMAOBMAOAKDM4EMAPT | |
| SCHEMBL5046828 | 0.81 | ACACB (0.48) | ACACB | |
| SCHEMBL5046911 | 0.77 | ACACB (0.53) | ACACB | |
| SCHEMBL5046845 | 0.76 | ACACB (0.56) | ACACBAPPMAPTRAB9A | |
| SCHEMBL5043653 | 0.76 | CA12 (0.46) | ACACBCTNNB1RAB9AKMT2A | |
| Benzothiophene SCHEMBL20531230 | 0.76 | ACACB (0.40) | ACACBMAOBMAOAMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459480-B2 | Benzodioxepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1682528-B1 | BENZO [b][1,4] DIOXEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20050113374-A1 | Benzodioxepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113374-A1 | Benzodioxepine derivatives | BBOX1, ACOX1, ACOX3 | ACACB 5/4885MAOB 4/4885MAOA 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.